Abstract
Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the elderly in industrialized countries. The “wet” AMD, characterized by the development of choroidal neovacularization (CNV), could result in rapid and severe loss of central vision. The critical role of vascular endothelial growth factor A (VEGF) in CNV development has been clearly demonstrated and clinically VEGF neutralization has become standard care for wet AMD. Recently, CCR3 was reported to play an important role in CNV development and CCR3 targeting was believed to be superior to VEGF targeting for CNV suppression. Our data in the present work show that blocking CCR3 by a small molecule CCR3 antagonist SB 328437 or CCR3-neutralizing antibodies does not inhibit CNV in the Matrigel CNV models of rat and mouse, whereas VEGF-neutralizing antibodies or rapamycin effectively suppresses CNV. These results question the role of CCR3 in CNV development and the therapeutic approach to suppress CNV by CCR3 targeting.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Brown DM, Kaiser PK, Michels M et al (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432–1444
Cao J, Zhao L, Li Y et al (2010) A subretinal matrigel rat choroidal neovascularization (CNV) model and inhibition of CNV and associated inflammation and fibrosis by VEGF Trap. Invest Ophthalmol Vis Sci 51:6009–6017
Chappelow AV, Kaiser PK (2008) Neovascular age-related macular degeneration: potential therapies. Drugs 68:1029–1036
Das A, McGuire PG (2003) Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition. Prog Retin Eye Res 22:721–748
Dejneka NS, Kuroki AM, Fosnot J et al (2004) Systemic rapamycin inhibits retinal and choroidal neovascularization in mice. Mol Vis 10:964–972
Emerson MV, Lauer AK (2007) Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema. BioDrugs 21:245–257
Ferrara N, Davis-Smyth T (1997) The biology of vascular endothelial growth factor. Endocr Rev 18:4–25
Grisanti S, Tatar O (2008) The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration. Prog Retin Eye Res 27:372–390
Klein R, Klein BE, Linton KL (1992) Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 99:933–943
Kwak N, Okamoto N, Wood JM et al (2000) VEGF is major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci 41:3158–3164
Li Y, Song Y, Zhao L et al (2008) Direct labeling and visualization of blood vessels with lipophilic carbocyanine dye DiI. Nat Protoc 3:1703–1708
Lin RC, Rosenfeld PJ (2007) Antiangiogenic therapy in neovascular age-related macular degeneration. Int Ophthalmol Clin 47:117–137
Penn JS, Madan A, Caldwell RB et al (2008) Vascular endothelial growth factor in eye disease. Prog Retin Eye Res 27:331–371
Qiu G, Stewart JM, Sadda S et al (2006) A new model of experimental subretinal neovascularization in the rabbit. Exp Eye Res 83:141–152
Rosenfeld PJ, Brown DM, Heier JS et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431
Rosenfeld PJ, Schwartz SD, Blumenkranz MS et al (2005) Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 112:1048–1053
Saishin Y, Takahashi K, Limae Silva R et al (2003) VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol 195:241–248
Takeda A, Baffi JZ, Kleinman ME et al (2009) CCR3 is a target for age-related macular degeneration diagnosis and therapy. Nature 460:225–230
Wen et al (2002) IOVS 2002; 43:ARVO E-abstract 1297
Zhao L, Wang Z, Liu Y et al (2007) Translocation of the retinal pigment epithelium and formation of sub-retinal pigment epithelium deposit induced by subretinal deposit. Mol Vis 13:873–880
Acknowledgments
This work was supported by grants from the James and Esther King Biomedical Research Program of the State of Florida (YL), National Institutes of Health (R01EY015289 to RW, R01EY018586 to RW), Hope for Vision (RW), and the Department of Defense (W81XWH-09-1-0674 to RW). It was also supported by NIH core grant P30EY14801 and an unrestricted grant from Research to Prevent Blindness Inc. to Bascom Palmer Eye Institute.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this paper
Cite this paper
Li, Y., Huang, D., Xia, X., Wang, Z., Luo, L., Wen, R. (2012). What Is the Role of CCR3 in Choroidal Neovascularization?. In: LaVail, M., Ash, J., Anderson, R., Hollyfield, J., Grimm, C. (eds) Retinal Degenerative Diseases. Advances in Experimental Medicine and Biology, vol 723. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-0631-0_36
Download citation
DOI: https://doi.org/10.1007/978-1-4614-0631-0_36
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4614-0630-3
Online ISBN: 978-1-4614-0631-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)